Close Menu

NEW YORK – With a pan-cancer local coverage determination for its Guardant360 test now finalized and US Food and Drug Administration approval anticipated in the first half of this year, Guardant Health has settled the major regulatory and reimbursement hurdles for its non-invasive advanced cancer genotyping and can now accelerate its efforts in cancer screening and early-stage adjuvant testing, and focus on new companion diagnostic associations for its flagship test.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.